Lindahl acted as legal advisor to Ziccum AB (publ) in connection with an Evaluation Agreement with a Biopharmaceutical Corporation focused on mRNA technologies, for ambient drying of mRNA/LNP materials and/or mRNA vaccine(s) with Ziccum’s proprietary LaminarPaceTM technology.
Under the agreement, Ziccum and the Biopharmaceutical Corporation will perform a fully financed feasibility study for formulating and drying mRNA/LNP materials and/or mRNA vaccine(s) with Ziccum’s proprietary LaminarPace ambient drying technology, to generate dry powder materials in mRNA/LNP technology development.
The agreement is a breakthrough for Ziccum and a milestone achievement in Ziccum’s strategy and capability to move partnering dialogues forward.
The agreement is the result of keen interest in the LaminarPace technology to generate dry powder materials in mRNA/LNP technology development, based on successful results on the mRNA/LNP platform for LaminarPace. LaminarPace is an entirely new drying technology making dry powder biopharmaceuticals possible. LaminarPace uses ambient drying (drying using mass transfer instead of heat), which is a new way of drying biologics that eliminates heat stress, heat degradation and the need for elevated temperatures.
The feasibility study is expected to start in May 2023.
Lindahl's team consisted of Hugo Norlén and Johanna Andersson.
Ziccum's press release is available here.